Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.

Abstract

Rotavirus gastroenteritis is a major cause of morbidity and mortality among African infants and young children. A phase III, placebo-controlled, multi-centre clinical trial of a live, oral G1P[8] human rotavirus vaccine (RIX4414) undertaken in Malawi and South Africa significantly reduced the incidence of severe rotavirus gastroenteritis in the first year… (More)
DOI: 10.1016/j.vaccine.2011.09.120

Topics

Cite this paper

@article{Cunliffe2012EfficacyOH, title={Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.}, author={Nigel A. Cunliffe and Desir{\'e}e Witte and Bagrey M.M. Ngwira and Stacy Todd and Nancy J Bostock and Ann Marie Turner and Philips Chimpeni and John C Victor and Andrew D. Steele and Alain R. Bouckenooghe and Kathleen M Neuzil}, journal={Vaccine}, year={2012}, volume={30 Suppl 1}, pages={A36-43} }